Alvotech Ordinary Shares (ALVO) Stock: Buy, Sell, or Hold?
ALVO - Alvotech Ordinary Shares
$5.45
-0.17 (-3.02%)
âŧ
5d:
-5.22%
30d:
+2.06%
90d:
+57.51%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ALVO is fairly priced but lacks strong directional signals. At 12.5% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ALVO is fairly priced but lacks strong directional signals. At 12.5% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.37
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $5.45, which is considered fair relative to its 30-day fair value range of $5.05 to $5.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.9) compared to its historical average (16.8). At these levels, the market is pricing in 12.5% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is currently testing key support at $5.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: ALVO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.80 (+24.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is currently testing key support at $5.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: ALVO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.80 (+24.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.05 -
$5.77
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
48.6%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 24.8% below Wall St target ($6.80)
- BULLISH: Expecting earnings turnaround to 12.5% growth with -38.9% revenue growth
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.05 -
$5.77
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.43
Resistance Level
$6.17
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.87
Wall Street Target
$6.80
(+24.8%)
Revenue Growth (YoY)
-38.9%
Earnings Growth (YoY)
-99.0%
Profit Margin
-36.3%
Valuation Premium vs History
+12.5% premium
PE vs Historical
23.9 vs 16.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.5%
(market-implied from PE analysis)
1-Year Target
$6.13
(+13%)
2-Year Target
$6.90
(+27%)
3-Year Target
$7.76
(+42%)
3-Yr Target (if PE normalizes)
(PE: 24â17)
PE COMPRESSION
$5.46
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 02, 2026 9:46 PM ET
Data refreshes hourly during market hours. Next update: 10:46 PM
Data refreshes hourly during market hours. Next update: 10:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
